W. Gordon

发表

The secretion of methadone and its major metabolite in the gastric juice of humans: comparison with blood and salivary concentrations.

W. P. Gordon, N. Gerber, R. Smith, 1976, Drug metabolism and disposition: the biological fate of chemicals.

New gas chromatographic assay for the quantification of methadone

W. P. Gordon, N. Gerber, R. Leger, 1977 .

Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.

T. Baillie, W. P. Gordon, A. Rettenmeier, 1985, Drug metabolism and disposition: the biological fate of chemicals.

Studies on the mechanism of acetamide hepatocarcinogenicity.

E Dybing, S. Thorgeirsson, J. Holme, 1987, Pharmacology & toxicology.

Interstrain differences of in vitro metabolic stability and impact on early drug discovery.

J. Isbell, M. Wogan, Wendy Richmond, 2010, Journal of pharmaceutical sciences.

Genotoxicity studies with paracetamol.

J. Holme, E. Dybing, E. Søderlund, 1984, Mutation research.

Excretion of phenytoin into semen of rabbits and man. Comparison with plasma levels.

W. P. Gordon, B. Swanson, N. Gerber, 1978, Drug metabolism and disposition: the biological fate of chemicals.

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts

Nanxin Li, G. Brodeur, W. P. Gordon, 2014, Cancer Chemotherapy and Pharmacology.

Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.

P. McNamara, Chun Xing Li, Yang Yang, 2014, Journal of medicinal chemistry.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2

Sungjoon Kim, Nanxin Li, M. Warmuth, 2013, Journal of medicinal chemistry.

Inhibitors of intracellular phosphatidic acid production: novel therapeutics with broad clinical applications

G. Rice, J. Bianco, J. Singer, 1994 .

Snapshot PK: a rapid rodent in vivo preclinical screening approach.

Bo Liu, Yingyao Zhou, John Isbell, 2008, Drug discovery today.

The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran.

W. P. Gordon, S. Nelson, R. Mcclanahan, 1987, Drug metabolism and disposition: the biological fate of chemicals.

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.

H. M. Petrassi, P. McNamara, Minhua Qiu, 2020, Journal of medicinal chemistry.

Metabolism in vitro of tris(2,3-dibromopropyl)-phosphate: oxidative debromination and bis(2,3-dibromopropyl)phosphate formation as correlates of mutagenicity and covalent protein binding.

J. Omichinski, E. Dybing, E. Søderlund, 1984, Biochemical pharmacology.

Activation mechanism of tris(2,3-dibromopropyl)phosphate to the potent mutagen, 2-bromoacrolein.

J. Omichinski, E. Dybing, E. Søderlund, 1984, Biochemical and biophysical research communications.

Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques.

T. Baillie, W. P. Gordon, A. Rettenmeier, 1989, Biomedical & environmental mass spectrometry.

Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds.

T. Tuntland, Bo Liu, Wendy Richmond, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Comparison of hepatic biotransformation and toxicity of allyl alcohol and [1,1-2H2]allyl alcohol in rats.

W. P. Gordon, J. M. Patel, K. Leibman, 1983, Drug metabolism and disposition: the biological fate of chemicals.